Table of Contents
| << Previous Issue | Jan 2012 (Vol: 2012, Issue: 1) | Next Issue >> |
- Section: Cartoons
-
Decision Maker
- Section: Features
-
Benchmarking – A Market Approach to Valuation
- Section: Licensing
-
Amgen Enters Biosimilars Market with Watson Pharmaceuticals Collaboration
-
Pharmacyclics Signs US$975 M Agreement with Janssen Biotech for Mid-Stage Btk Inhibitor
-
Merck & Co. Licenses Exelixis’ PI3K-Delta R&D Programme
-
AstraZeneca Signs Two Deals to Reinforce its Pipeline After Development Setbacks
-
Biogen Idec Options Isis Pharmaceuticals’ Antisense Drug for Spinal Muscular Atrophy
- Section: Mergers & Acquisitions
-
Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands
-
Takeda to Gain Selective PI3K and mTOR Inhibitors via Intellikine Acquisition
-
BMS Adds Nucleotide Analogue to its HCV Pipeline with US$2.5 B Inhibitex Acquisition
- Section: Opinion & Analysis
-
ANNUAL REVIEW: Deal Making in 2011
- Section: Research & Development
-
Reata Pharmaceuticals Partners Again with Abbott for US$400 M Upfront
-
Baxter and Momenta Form Global Collaboration to Develop and Commercialise Biosimilars
-
Karo Bio and Pfizer Form Research Collaboration to Discover and Develop ROR-Gamma Modulators
- Section: Technology Access
-
Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators
RSS